HS-001
AssetAlso called HS-001 CS
Transplanted allogeneic iPSC-derived cardiomyocyte spheroids regenerate heart muscle to improve cardiac function.
- Stage
- Phase 1
- Modality
- Cell therapy
- Target
- Not known
- 4
- Indications
- 2
- Trials
- 1
- Developer
Trial NCT07347197 is still running. Trial NCT07347197 updated in its registry on Oct 22, 2026. clinicaltrials.gov
Indications
4Heart failure
Phase 1, Completed, NCT04945018, clinicaltrials.gov, Oct 23, 2026
Ischemic heart disease
Phase 1, Completed, NCT04945018, clinicaltrials.gov, Oct 23, 2026
Dilated cardiomyopathy
Phase 1, Recruiting, NCT07347197, clinicaltrials.gov, Oct 23, 2026
1 more
In the full profile
- Owner and partners1
- Trials2
- Competitors8
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.